Moreover, the 36-month beta value for ELEV is 1.25. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ELEV is 49.99M and currently, short sellers hold a 12.53% of that float. On October 04, 2024, ELEV’s average trading volume was 1.23M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ELEV) stock’s latest price update
Elevation Oncology Inc (NASDAQ: ELEV)’s stock price has plunge by -9.40relation to previous closing price of 0.57. Nevertheless, the company has seen a -9.51% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-23 that BOSTON, Sept. 23, 2024 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed on or after prior therapy.
ELEV’s Market Performance
Elevation Oncology Inc (ELEV) has seen a -9.51% fall in stock performance for the week, with a -22.21% decline in the past month and a -81.73% plunge in the past quarter. The volatility ratio for the week is 10.18%, and the volatility levels for the past 30 days are at 8.49% for ELEV. The simple moving average for the last 20 days is -13.06% for ELEV stock, with a simple moving average of -80.56% for the last 200 days.
Analysts’ Opinion of ELEV
Many brokerage firms have already submitted their reports for ELEV stocks, with Piper Sandler repeating the rating for ELEV by listing it as a “Overweight.” The predicted price for ELEV in the upcoming period, according to Piper Sandler is $10 based on the research report published on May 31, 2024 of the current year 2024.
Stephens, on the other hand, stated in their research note that they expect to see ELEV reach a price target of $8. The rating they have provided for ELEV stocks is “Overweight” according to the report published on May 14th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to ELEV, setting the target price at $7 in the report published on March 01st of the current year.
ELEV Trading at -49.51% from the 50-Day Moving Average
After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.07% of loss for the given period.
Volatility was left at 8.49%, however, over the last 30 days, the volatility rate increased by 10.18%, as shares sank -19.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -79.66% lower at present.
During the last 5 trading sessions, ELEV fell by -9.51%, which changed the moving average for the period of 200-days by +2.08% in comparison to the 20-day moving average, which settled at $0.5925. In addition, Elevation Oncology Inc saw -3.04% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ELEV
Current profitability levels for the company are sitting at:
- -684.45 for the present operating margin
- 0.43 for the gross margin
The net margin for Elevation Oncology Inc stands at -684.53. The total capital return value is set at -0.35. Equity return is now at value -51.87, with -35.30 for asset returns.
Based on Elevation Oncology Inc (ELEV), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is -8.28.
Currently, EBITDA for the company is -40.3 million with net debt to EBITDA at 0.72. When we switch over and look at the enterprise to sales, we see a ratio of 38.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 41.10.
Conclusion
To wrap up, the performance of Elevation Oncology Inc (ELEV) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
